Novartis AG (SWX:NOVN)
91.68
+0.77 (0.85%)
May 12, 2025, 5:39 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.62B USD in the quarter ending March 31, 2025, with 12.38% growth. This brings the company's revenue in the last twelve months to $53.22B, up 11.50% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$53.22B
Revenue Growth
+11.50%
P/S Ratio
3.79
Revenue / Employee
$701.37K
Employees
75,883
Market Cap
178.12B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Lonza Group AG | 6.57B |
Alcon | 8.98B |
Galderma Group AG | 4.02B |
Straumann Holding AG | 2.50B |
Sandoz Group AG | 9.41B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 617.07M |
Novartis AG News
- 11 hours ago - Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know - CNBC
- 14 hours ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 21 hours ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 23 hours ago - Novartis to keep making malaria drugs if orders dry up amid aid cuts - Reuters
- 3 days ago - Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks. - Barrons
- 6 days ago - China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief - Financial Times
- 6 days ago - PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Benzinga
- 7 days ago - BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion - Benzinga